One of the primary factors likely to drive growth of the global epinephrine market is the increase in pipeline epinephrine medicines. Greater air pollution, which leads to a rise in the prevalence of respiratory disorders, is expected to boost the global market. The rising frequency of cardiovascular illnesses, cardiac arrest, and other similar conditions is likely to drive the market in the years to come. The global epinephrine market is predicted to develop in response to rising awareness about health.
The Adrenal Medulla produces the active hormone epinephrine. Both alpha and beta adrenergic systems are stimulated by epinephrine. Epinephrine aids heart stimulation, systemic, bronchi vasoconstriction dilation, and gastric relaxation and all these benefits are expected to foster growth of the global epinephrine market.
Pre-filled syringes are the most common type of epinephrine. Anaphylaxis, hypotension linked with respiratory disorders, cardiac arrest, septic shock, and other conditions are among the conditions for which epinephrine is prescribed. Epinephrine injections are commonly offered as a solution-filled prefilled automated injection device. The epinephrine can be delivered intravenously, subcutaneously, or intramuscularly.
Disease type, application, and region are important factors in the market that has been considered for the classification of the global epinephrine market.
In August 2018, Teva Pharmaceuticals has gained FDA clearance for the first generic variants of EpiPen and EpiPen Jr, which are used to manage allergic responses in adult and children patients weighing over 33 pounds.
Some of the major players in the global epinephrine market are as mentioned below
Below-mentioned developments, restraints, opportunities, and drivers are anticipated to characterize the global epinephrine market
Epinephrine is an antihistamine that is utilized in conjunction with medical emergency therapy to treat allergic responses to insect stings or bites, medications, latex, and food products amongst many other things. It acts by calming the airway muscles and constricting the blood vessels. The injection comes in a prefilled automated injection device with the solution, as well as subcutaneous injection vials and other forms. At the first symptom of an acute allergic response, the injection is usually given as needed. Epinephrine's rise in the healthcare industry is due to an increase in anaphylaxis incidents, and the launch of a generic form of epinephrine is likely to stimulate growth of the global epinephrine market in the coming years. The absence of epinephrine auto injectors as well as low-cost substitutes, on the other hand, is expected to have a negative influence on market growth in the years to come.
The incidence of chronic respiratory disorders is expected to rise, thereby likely to boost development of the global epinephrine market. Epinephrine comes in a variety of dosages and concentrations for various methods of administration and indications, including respiratory problems. Chronic respiratory diseases (CRDs) impact more than 1 billion people globally, as per the WHO (World Health Organization), and asthma is a major cause, impacting the elderly population, adults, and children throughout their lives. According to the WHO, over 300 million people worldwide suffered with asthma in 2013, and this number is anticipated to rise to over 400 million by 2025. Such high prevalence of respiratory diseases to bolster expansion of the global epinephrine market in the years to come.
Due to the presence of sophisticated healthcare facilities as well as treatment processes adopted in North America (notably the US), Asia Pacific, and Europe, is likely to account for significant revenue shares in the global epinephrine market. Due to its expanding population, Europe is predicted to be another important region in the global market. Due to growing healthcare understanding as well as rising research and development efforts, Asia Pacific is expected to account for a substantial revenue share in the global epinephrine market.
N/A